In vivo drug interactions of the teratogen thalidomide with midazolam: Heterotropic cooperativity of human cytochrome P450 in humanized TK-NOG mice

Chemical Research in Toxicology

Volumn 26, Issue 3, 2013, Pages 486-489

  Yamazaki, Hiroshi ^a   Suemizu, Hiroshi ^b   Murayama, Norie ^a   Utoh, Masahiro ^a   Shibata, Norio ^c   Nakamura, Masato ^b   Guengerich, F Peter ^d  

^a SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

^b CENTRAL INSTITUTE FOR EXPERIMENTAL ANIMALS   (Japan)

^c NAGOYA INSTITUTE OF TECHNOLOGY   (Japan)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; CYTOCHROME P450 3A; GANCICLOVIR; MIDAZOLAM; THALIDOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CHILD; CHIMERA; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; ENZYME INDUCTION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRESCHOOL CHILD; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE;

ADJUVANTS, ANESTHESIA; ANIMALS; CHIMERA; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER; MALE; MICE; MIDAZOLAM; TERATOGENS; THALIDOMIDE;

EID: 84875146624     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx400008g     Document Type: Article

References (11)

1. Rendic, S. and Guengerich, F. P. (2010) Update information on drug metabolism systems-2009, part II: Summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters Curr. Drug Metab. 11, 4-84
2. Calabrese, L. and Resztak, K. (1998) Thalidomide revisited: Pharmacology and clinical applications Expert Opin. Invest. Drugs 7, 2043-2060
3. Kim, J. H. and Scialli, A. R. (2011) Thalidomide: The tragedy of birth defects and the effective treatment of disease Toxicol. Sci. 122, 1-6
4. Trapnell, C. B., Donahue, S. R., Collins, J. M., Flockhart, D. A., Thacker, D., and Abernethy, D. R. (1998) Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone Clin. Pharmacol. Ther. 64, 597-602
5. Okada, Y., Murayama, N., Yanagida, C., Shimizu, M., Guengerich, F. P., and Yamazaki, H. (2009) Drug interactions of thalidomide with midazolam and cyclosporine A: Heterotropic cooperativity of human cytochrome P450 3A5 Drug Metab. Dispos. 37, 18-23
6. Chowdhury, G., Murayama, N., Okada, Y., Uno, Y., Shimizu, M., Shibata, N., Guengerich, F. P., and Yamazaki, H. (2010) Human liver microsomal cytochrome P450 3A enzymes involved in thalidomide 5-hydroxylation and formation of a glutathione conjugate Chem. Res. Toxicol. 23, 1018-1024
7. Yamazaki, H., Suemizu, H., Igaya, S., Shimizu, M., Shibata, M., Nakamura, M., Chowdhury, G., and Guengerich, F. P. (2011) In vivo formation of a glutathione conjugate derived from thalidomide in humanized uPA-NOG mice Chem. Res. Toxicol. 24, 287-289
8. Yamazaki, H., Suemizu, H., Shimizu, M., Igaya, S., Shibata, N., Nakamura, N., Chowdhury, G., and Guengerich, F. P. (2012) In vivo formation of dihydroxylated and glutathione conjugate metabolites derived from thalidomide and 5-hydroxythalidomide in humanized TK-NOG mice Chem. Res. Toxicol. 25, 274-276
9. Hasegawa, M., Kawai, K., Mitsui, T., Taniguchi, K., Monnai, M., Wakui, M., Ito, M., Suematsu, M., Peltz, G., Nakamura, M., and Suemizu, H. (2011) The reconstituted 'humanized liver' in TK-NOG mice is mature and functional Biochem. Biophys. Res. Commun. 405, 405-410
10. Eriksson, T., Bjorkman, S., Roth, B., Bjork, H., and Hoglund, P. (1998) Hydroxylated metabolites of thalidomide: Formation in-vitro and in-vivo in man J. Pharm. Pharmacol. 50, 1409-1416
11. Schumacher, H., Smith, R. L., and Williams, R. T. (1965) The metabolism of thalidomide: The fate of thalidomide and some of its hydrolysis products in various species Br. J. Pharmacol. Chemother. 25, 338-351